The BK polyomavirus was isolated in 1971; it has been a significant risk factor for both graft dysfunction and failure in renal transplant recipients. So far, no specific treatment option has been available for effective treatment or prophylaxis for BK virus infections. Although the use of heavy immunosuppression has been the main risk factor for BK virus infection, other risk factors are equally important, including elderly recipients, prior rejection episodes, male sex, human leukocyte antigen mismatching, prolonged cold ischemia time, pretransplant BK virus serostatus, and ureteral stenting. Regular follow-up for BK virus infections according to each institution’s policy has been, so far, effective in detecting patients with BK virus viremia and consequently preventing allograft loss. The mainstay of management continues to be reduction of immunosuppression. However, newer options are providing new insights, such as cellular immunotherapy. In this review, we will address the diagnosis, screening, new diagnostic tools, and updated management of BK virus infections.
Key words : Graft dysfunction, Immunosuppression, Polyomavirus, Renal failure
Introduction
Polyomaviruses are small DNA viruses that can infect humans and animals like rabbits, rodents, and birds. BK polyomavirus (BKV) is considered one of the highly prevalent forms of polyomaviruses causing infection in humans, especially in immunocompromised patients. In renal transplant recipients, BKV can lead to tubulointerstitial nephritis and ureteral stenosis; it can also lead to hemorrhagic cystitis in bone marrow transplant patients.1 The current consensus on management of BKV viremia is to decrease immunosuppression, to have regular follow-up of BKV polymerase chain reaction (PCR), and to have continuous monitoring of renal functions in an attempt to prevent allograft BKV nephropathy (BKVN), which could subsequently increase the risk of graft failure. The challenging part in the management of BKV infection is the balance between the fear of rejection due to reduction of immunosuppression and the maintenance of immunosuppression at the same level, which could cause more BKV viremia and consequently BKVN.2
BK virus is one of the most common infections in renal transplant recipients.3-5 Every institution has its own local policy for screening BKV infection; however, most institutions tend to reduce immunosuppression to control BKV viremia, with few institutions following a preemptive immunosuppression reduction policy.6-8 Reports have shown that BKVN management with reduction of immunosuppression has been effective in preserving allograft function.9,10
Virology
Properties
BK virus is a member of the family Polyomaviruses. This family is a
double-stranded DNA virus with icosahedral symmetry. BK virus has been
categorized serologically and genotypically into 4 groups (I to IV), with each
one having a different virulence.11
Historical aspects
In 1971, a Sudanese renal transplant patient “whose initials were given for the
virus” was diagnosed with BKV infection when he presented with ureteral
obstruction after renal transplant. When the ureters were examined under
electron microscopy, viral particles were seen in the lining of the ureters. In
addition, a high BKV antibody titer was detected in the patient’s serum.12
Genome structure and transcription
Polyomaviruses are small (40-50 nm in diameter), uncovered, icosahedrals, with a
double circular chain. Their genome is about 5000 base pairs, contained in the
histones derived from host cells. When exposed to high temperature, their
particles are stable, thus retaining their ability to infect. The external layer
consists of structural proteins VP1, VP2, and VP3. VP1 is organized into 72
pentamers, each one associated with a unique copy of smaller structure proteins
(VP2 or VP3). VP1 determines receptor specificity, whereas VP2 and VP3 are
involved in viral particle stabilization outside the host cell and transport
within it. The genomic structure encodes 6 chief proteins divided into 3
regions: early encoding region, late encoding region, and noncoding control
region.13
Transmission mechanism
Primary BKV infection occurs in the first decade of life, on average at 4 to 5
years of age. Possible routes include the following: (1) airborne transmission
through air droplets14; (2) a feco-oral transmission, as fecally eliminated
polyomaviruses are detected in hospitalized children; (3) other mechanisms,
including urinary-oral route or seroconversion after solid-organ transplant
(such as renal transplantation)15; and (4) both through blood transfusion and
vertical transmission; these have been considered routes for BKV transmission as
BKV DNA has been found in the placenta, brain, and renal tissue of aborted
fetuses.16,17
Primary polyomavirus infections usually occur during childhood through respiratory or oral routes.18 Primary infections are often clinically insignificant; however, the virus stays in the renal epithelium, including in tubular, parietal, and transitional structures and in Bowman’s capsule.19 In the immunocompetent population, BKV replication is manifested by asymptomatic viruria, and the incidence of shedding is 20%. However, in immunocompromised individuals, the risk of shedding reaches 60% and the viruria is more common.20,21 Patients with impaired cell-mediated immunity have a particularly greater risk of BKV infection; these patients include pregnant women where viral shedding usually disappears 2 weeks after delivery.22 The mean prevalence of BKVN in renal transplant recipients is 5%, whereas the prevalence of ureteral stenosis is less.23
Risk factors and pathogenesis
The most important risk factor for developing BKV disease is the degree of
immunosuppression rather than the type of immunosuppression used. Transplant
physicians consider BKV infection as a marker of heavy immunosuppression.24
Active BKV disease has been associated with various immunosuppression protocols,
most commonly tacrolimus and mycophenolate mofetil based.25,26 Other studies
have suggested that BKV disease can occur with any immunosuppression
medication.27,28 In addition, immunosuppressive agents can affect T cells,
which can lead to increased BKV replication. Tacrolimus specifically can
increase BKV replication by a specific mechanism involving FK-binding protein
(BP-12).29 Other risk factors that could be involved, although not commonly,
include diabetes mellitus, delayed graft function, treated episodes of acute
rejection, ureteral trauma, use of antilymphocyte antibodies, coinfection with
Cytomegalovirus (CMV), maintenance steroid immunosuppression, older age, white
race/ethnicity, and presence of specific human leukocyte antigen (HLA) C
loci.30-32 Of note, the presence of BKV antibody titers in donors, which
reflects recent BKV reactivation and replication, is another risk factor. The
viruria in a potential donor can be considered as a predictor for posttransplant
BKV infection.
Recent studies have demonstrated that BKV replication in a transplant recipient is usually due to transmitted infection from the donor.30 Both HLA and ABO-incompatible transplants carry a higher risk of BKV nephropathy, possibly due to heavy immunosuppression (whether due to induction or maintenance immunosuppression or episodes of rejection). In 2004, Awadalla and associates demonstrated that renal transplant recipients who have HLA-incompatible transplant have increased incidence of rejection; this is especially shown in patients who were steroid resistant or treated with antilymphocyte treatment.33 Similarly, ABO-incompatible recipients are at a higher risk of BKVN than HLA-mismatched recipients as they may have a higher rate of rejection and need more immunosuppression than HLA-incompatible patients. In a study that compared 62 ABO-incompatible and 221 HLA-incompatible kidney transplant recipients, 17.7% versus 5.9% recipients developed BKVN, respectively.32
Clinical Picture of BK Virus Infection
About 90% of the population will become BKV seropositive during their life; this
reactivates after solid-organ transplant, especially in bone marrow or kidney
transplant recipients. In kidney transplant recipients, reactivation may lead to
BKVN, which may end with graft dysfunction and failure by causing
tubulointerstitial nephritis and/or ureteral obstruction. In bone marrow
transplant recipients, BKV can lead to hemorrhagic cystitis. It is quite
rare to have BKV reactivation in other immunocompromised patients, such as
those with human immunodeficiency virus, systemic lupus, or other autoimmune
diseases (Table 1).
Clinical manifestations are as follows: (1) asymptomatic, (2) slow and progressive increase of serum creatinine, and (3) an unsuspected finding of progressive renal damage (BKVN) on surveillance renal allograft biopsy.34 Importantly, no signs and symptoms are identified with BKV infection. Usually, BKV infection occurs 10 to 13 months posttransplant. BK virus nephropathy may occur earlier at week 1 posttransplant or as late as 5 years posttransplant.35
Laboratory findings in patients with BKV infection are as follows: (1) elevated serum creatinine and (2) urine analysis with pyuria, hematuria, and findings consistent with interstitial nephritis as cellular casts composed of renal tubular cells and inflammatory cells. However, these results could be normal.
Diagnosis Overview
A tissue (renal) biopsy is needed for a definitive diagnosis of BKVN; however, a
diagnosis may be missed in the tissue obtained because viropathic lesions are
patchy. In addition, for BKV, tropism is medulla, not the cortex, which may
increase the risk of missing the viropathic lesions. Quantitative
PCR is used to diagnose BKV viremia, which demonstrates BKV replication whether
there is renal involvement or not. BK virus nephritis is suspected when the
clinical diagnosis of tubulointerstitial nephritis is suspected; however, there
are no clinical features of tubulointerstitial nephritis that are unique to
BKVN. The presence of decoy cells in the urine analysis increases the suspicion
of BKV nephritis, which should be followed by quantitative PCR of blood
preferable to urine (Figure 1).
Different pathological patterns and associations with BKV infection are also shown in Figures 2 to 7.
Definitive diagnosis of BK virus nephropathy
A definitive diagnosis of BKVN requires characteristic cytopathic changes on the
renal biopsy plus positive immunohistochemistry (against BKV or against
SV40 large T antigens), which has a specificity of 100%, and pathognomonic
results for BKV infection (Figure 6).36,37 A diagnosis of BKV in a renal biopsy
could be missed in about 30% of cases because BKV has a focal tropism in the
medulla rather than in the cortex, making an initial biopsy not enough to
exclude the diagnosis of BKVN if highly suspicious.38,39 In the absence of
definitive criteria for BKVN diagnosis (Table 2), a presumptive diagnosis can be
done if there is sustained (more than 2-week duration) urinary viral shedding
and significant BKV replication (plasma DNA PCR load > 10 000 copies/mL), as
detected using a specific assay with or without kidney dysfunction; these
characteristics have been proposed to define presumptive BKVN.36,38 Moreover,
BKVN can be graded into 3 grades using Banff criteria according to the
percentage of fibrosis and the amount of viral replication (Table 3).
In BKVN, light microscopy examinations would show the following: (1) basophilic intranuclear viral inclusions without a surrounding halo (Figure 7)21,40; (2) anisonucleosis, hyperchromasia, and chromatin clumping of infected cells21,40; (3) areas of tubular damage showing interstitial mononuclear or polymorphonuclear cell infiltrates (Figure 2)21,40; (4) tubular injury in the form of tubular cell apoptosis, desquamation, and flattened epithelial lining21,40; and (5) tubulitis with lymphocyte invasion to the basement membrane of the tubular epithelium. When extensive, it is difficult to differentiate between BKVN and allograft rejection (Figure 2).21,40
In BKVN, electron microscopy examinations would show the following: (1) viral inclusions with diameter size ranging from 30 to 50 nm and (2) tubular damage, including tubular cell necrosis, prominent lysosomal inclusions, and luminal protein and cellular casts.40,41,49
Differential diagnosis
BK virus infection can be similar to other types of viral infections (CMV,
herpes simplex virus, adenovirus). Therefore, to confirm a diagnosis of BKVN, a
blood quantitative PCR showing > 60 to 100 BKV copies plus characteristically
pathologic morphology results are needed. Different pathological patterns and
associations with BKV infection are shown in Figures 2 to 7.
Urine cytology findings for BK virus infections
Urine examinations may reveal BKV-infected cells. The most characteristic
abnormality of infected cells is an enlarged nucleus with a single, large
basophilic intranuclear inclusion (Figure 1).34,42
The presence of characteristic cytopathologic changes in infected cells (which have been called decoy cells due to their similarity to renal carcinoma cells) is strongly suggestive of polyomavirus infections.43,44 Viral replication in the urine is demonstrated by either decoy cells or BKV urine quantitative PCR.36
Cytological urine abnormalities (decoy cells) are suggestive but not specific, sensitive, or definitive for BKV infection because (1) decoy cells can be present in other renal viral infections (such as CMV or adenovirus42) and (2) decoy cells correlate poorly with biopsy-proven BKVN in renal transplant recipients.44 Of note, their absence does not exclude the disease.35
Quantitative polymerase chain reaction
Sustained high viral DNA levels in the plasma of renal transplant recipients who
have an appropriate clinical picture can suggest BKVN. In a study of 78 renal
transplant patients, the sensitivity and specificity of quantitative PCR
analyses in detecting BKV DNA were about 100% and 88%, respectively.44 In
another study, 9 of 9 transplant recipients with biopsy-proven BKVN had BKV DNA
detected in plasma by PCR.45 However, such DNA was found
in only 2 of 41 transplant recipients without nephropathy and in 0 of 17
nontransplant patients with advanced human immunodeficiency virus-1 infection.
Viral DNA disappeared with decreased immunosuppression.
Renal transplant recipients can be monitored with quantitative or real-time PCR for BKV infections in either the plasma or urine.46,47 Multiple retrospective and prospective studies have agreed that viruria precede viremia by 4 weeks.46-48 Viral replication in the urine as detected by either analysis of urine cytology or demonstration of the virus by quantitative PCR has been shown to be present in 20% to 60% of renal transplant recipients, depending on the method of detection.36 During the first 6 months, 10% to 30% of renal transplant recipients may show levels of BKV viremia; however, BKV viremia can decrease later to 5% to 10% of renal transplant recipients. One study showed that 2% to 10% of renal transplant recipients had no BKVN 12 weeks after BKV viruria.36 Patients with a higher viruria level are highly prone to developing BKV viremia, and patients with high sustained viremia are susceptible to BKVN. In another study, although the risks of viremia and sustained viremia were 3- and 13-fold higher if the urine DNA level was > 9.5 log10 copies/mL, the sensitivity, specificity, positive predictive value, and negative predictive values of urine levels were 70%, 70%, 53%, and 83% for any viremia and 91%, 66%, 33%, and 98% for sustained viremia, respectively.6 In addition, a strong correlation was shown between the negativity of urine BKV PCR and blood BKV PCR.50 BK virus DNA levels can alter weekly by 1 to 2 log-folds depending on the commercially available PCR assay. It is recommended that medical decisions, especially those with regard to alterations of immunosuppression, be made on the basis of trends in quantitative DNA levels rather than on a single measurement.20
Serology
It is not helpful to examine serum for anti-BKV antibodies for a definitive
diagnosis of BKV infection because positivity for these antibodies is quite
common in the general population.9,51 During BKV infection, there are high
levels of BKV (immunoglobulin G [IgG]) titers during the first 6 weeks of
infection or 2 years after primary infection.51,52 The risk of developing higher
levels of BKV IgG is directly correlated with donor anti-BKV antibody
positivity.52 Anti-BKV antibody does not seem to be protective; therefore, it
can increase in both primary infections and reactivation of infections.30
Previous BKV seropos-itivity in the recipient can affect progression of BKV
infection, especially progression from viruria to viremia, which is considered a
harbinger of BKVN.53 In the laboratory, the intensity of infection can be
classified according to the type of antibody response: IgG, IgM, or IgA.53 The
utility of assessing anti-BKV antibody levels before and after transplant is not
clear. The utility of conducting BKV serology examinations before and after
transplant is controversial because it is not entirely clear which antibodies
are neutralizing.54,55 The risk of developing a clinically significant BKV
infection is high when transplant is performed between a positive BKV donor and
a negative recipient.
Viral culture
Viral culture is rarely used as a method for BKV infection detection outside the
research setting. Viral isolation from the clinical specimen can take weeks to
months; therefore, this method is not clinically applicable.56
Urine electron microscopy
Urine examinations using negative-staining electron microscopy for patients with
BKV infection will show cast-like 3-dimensional polyomavirus aggregates, which
are called Haufen (Figure 8).57 In a retrospective single-center study, Haufen
presence was shown to be associated with 100% sensitivity and 99% specificity
for biopsy-verified BKVN in kidney transplant recipients.57 In addition, a
relationship was reported among Haufen, high-level BKV viremia (median copy
1 206 325 copies/mL), and the occurrence of acute kidney injury and BKVN.
However, urine analyses in patients with a low viremia (median of 26 959
copies/mL) did not show Haufen bodies. Thus, urinary Haufen bodies can act as a
noninvasive method for BKVN diagnosis in renal transplant recipients. This
diagnostic technique is of a great utility, especially in differentiating
between BKVN and asymptomatic BKV infection. However, it remains to be
determined whether this method can be used for diagnosis as it depends on a
sophisticated analysis and it also requires a meticulous interpretation by
pathologists. In addition, the study did not determine whether urine electron
microscopy can discriminate between rejection and BKVN.57 Despite these
limitations, the presence of a high load of Haufen with equivocal biopsy would
highly support the possibility of BKVN rather than rejection as a cause of
allograft dysfunction, which could support medical decisions of reduction of
immunosuppression rather than augmentation as in cases of rejection.
Therapeutic Interventions
Few controlled studies are available to guide us through the management of BKV
infection in renal transplantation.58 Currently, there are no available
antiviral medications against BKV. However, potential anti-BKV agents have been
suggested by several reports. Concomitant administration of these agents with
immunosuppression reduction was only documented in uncontrolled retrospective
observational studies; therefore, it is difficult to make firm conclusions
about their therapeutic efficacy. The usual approach in the management of BKV
viremia or BKVN in renal transplant recipients is the reduction of
immunosuppression and continuous monitoring of BKV viremia levels using
quantitative PCR.9,59 Various therapeutic interventions are discussed in the
following sections.
Immunosuppression reduction
Despite the fact that reduction of immunosuppression has been the cornerstone
in the management of BKV infection, it also carries a higher risk of rejection,
making this decision challenging. Histologically, there is a similar feature
between rejection and BKVN, which often shows severe interstitial inflammation
in addition to the presence of viral inclusions and SV40 immunohistochemistry
may become negative.60 Moreover, modification of immunosuppression to treat BKV
infection carries a higher incidence of long-term chronic rejection. One study
suggested that patients with persistent sustained BKV viremia are prone to the
development of de novo donor-specific anti-HLA antibodies.
Cidofovir
Multiple single-center studies and case series have described the benefits of
adding cidofovir with immunosuppression reduction. However, no randomized
controlled trials are available to support this approach.61,62 One of the
limitations of this approach is nephrotoxicity, thus making the decision to use
cidofovir unlikely.
Brincidofovir (CMX001)
Because of the nephrotoxicity with cidofovir, scientists had developed
brincidofovir, which is a prodrug of cidofovir that is administered orally.
Phase 3 clinical trials have shown a lower incidence of nephrotoxicity with
brincidofovir.63 Successful outcomes in renal and hematopoietic transplant have
been described in multiple case reports after treatment of BKVN with
brincidofovir.64,65 However, larger-scale clinical trials are needed to
establish
the safety and efficacy of brincidofovir in the management of BKVN patients.
Leflunomide
Leflunomide is an immunosuppressant agent that also has antiviral properties
against BKV in vitro.66 Several case series have utilized it as a replacement
agent in lieu of mycophenolate.67,68 These studies have shown a significant
association between leflunomide and decrease in BKV viral load; however, this
does not reflect the cause of BKV viral load (that is, whether it is a result of
immunosuppression reduction or due to the antiviral properties of leflunomide).
Side effects of leflunomide include thrombotic microangiopathy, hepatitis, and
bone marrow suppression.67 The active metabolite of leflunomide (known as
teriflunomide or A771726) can be measured, which can be helpful in continuous
monitoring of the level of leflunomide and avoid toxicity.68 In a case series,
achieving a level of 50 to 100 g/mL of teriflunomide or A771726 was associated
with a reduction of BKV viral load, as shown in a follow-up of 22 renal
transplant patients.69 Further prospective controlled studies of leflunomide are
needed to confirm the efficacy and safety of this drug against BKV infection70
Intravenous immunoglobulin
Intravenous immunoglobulin (IVIG) contains neutralizing antibodies against BKV,
which makes it a good choice in the management of BKVN.71 The evidence of using
IVIG as adjunctive therapy for BKVN has been described in multiple case reports
and case series72,73; however, no controlled studies have been reported. In
patients with hypogammaglobulinemia, IVIG therapy was beneficial with regard to
anti-BKV immunity; the immunomodulatory effects of IVIG may guard against
allograft rejection in the context of reduced immunosuppression.74
Fluoroquinolone
In vitro studies have shown that fluoroquinolone antibiotics can inhibit
replication of BKV or SV40 polyomavirus replication in vitro; therefore,
fluoroquinolone antibiotics have been considered as potential agents for
controlling BKV infection in renal transplant recipients.75,76 In vitro studies
have revealed that fluoroquinolones appear to have an inhibitory effect through
reduction of large T antigen expression and inhibition of large T antigen
helicase activity.75,76 In a retrospective study of fluoroquinolone given as
prophylaxis against BKV infection in
renal transplant recipients, fewer renal transplant recipients who received the
fluoroquinolone developed BKV viremia, supporting the probability that
fluoroquinolone may have a role in preventing BKV replication.77,78 A
single-center nonrandomized study demonstrated that coadministration of
ciprofloxacin and leflunomide were successful in controlling BKV infections.79
However, other prospective randomized trials showed no benefit from levofloxacin
in renal transplant recipients to control BKV infection.80-82 Overall, these
data suggest that fluoroquinolones do not currently have a clinically
significant role in the management of BKV-related diseases.82
Role of cellular immunotherapy in the management of BKV infection
BK virus infections usually occur during childhood; BKV then becomes dormant
until it is reactivated after immunosuppression treatment as a result of failure
of BKV-reactive T cells to control viral replication.83 Therefore, the idea of
this approach depends on the transfer of primed BKV-reactive
T cells, which may help in controlling the
BKV-associated disease. In the early 1990s, Riddell and associates were the
first team to start cellular therapy using T cells to restore antiviral immunity
in immunocompromised patients.84 Since then, various research teams have refined
new approaches for treating various chronic virus-associated diseases using the
adoptive T-cell therapy approach.85,86 Identifying viral immunogenic antigens is
necessary for successful generation of virus-specific T cells. Herpesviruses
immunodominant epitopes have been defined as researchers successfully used
synthetic viral peptides or overlapping peptide pools to produce CMV- or
Epstein-Barr-specific T cells.87 Newer advanced techniques have been developed
using interferon-capture technology or major histocompatibility complex
multimers88,89 to allow rapid selection and virus-specific T-cell enrichment.90
Research on treating BKV-associated diseases using immunotherapeutic approaches
is still in the early stages, and data on immunodominant BKV epitopes for T-cell
priming are limited. Blyth and associates recently reported the use of
overlapping peptide pools derived from all 5 BKV antigens to expand BKV-specific
human T cells.91 Functional characterization of the expanded T-cell population
confirmed BKV reactivity, cytokine production, and in vitro cytotoxicity.91 In a
pilot study published in 2014, in vitro expansion of virus-reactive T cells was
performed by use of overlapping peptide pools that included antigens from
Epstein-Barr virus, CMV, adenovirus, BKV, and human herpesvirus 6.92 Generated
cell products using this protocol were given to patients after hematopoietic
stem cell transplant either prophylactically or in response to single or
multiple viral infections. Few participants had active BKV infection, which
improved after adoptive T-cell transfer.92 This study has paved the way to the
possibility of management of BKV infection using the adoptive transfer of
BKV-reactive T cells.
Conclusions
BK virus is a member of human polyomaviruses, which are DNA viruses; BKV infections lead to tubulointerstitial nephritis and ureteral stenosis in the renal transplant population. The average incidence is about 10% of the renal transplant population.
There is a direct correlation between the incidence of BKV infection and the degree of immunosuppression, but not the drug itself. Other risk factors include diabetes mellitus, elderly patients, male patients, delayed graft function, acute rejection episodes, and previous CMV infections.
Clinical manifestations of BKV infection range from being asymptomatic to frank nephropathy with disturbed renal function and progressive increase of serum creatinine levels. Urine analysis may show hematuria, pyuria, and cellular casts. Urine microscopy shows decoy cells that are BKV-infected cells. A definitive diagnosis of BKVN is made by renal allograft biopsy using immunohistochemistry, which cross-react with the BKV, specifically SV40 large-T antigen part of the virus. BK virus nephropathy could be missed in about one-third of patients; therefore, 2 core biopsies are needed for confirmation, preferably including the medulla. Renal transplant recipients are usually monitored by serum and urine quantitative PCR for BKV DNA. Viral replication goes through stages, with viruria preceding viremia by about 4 weeks and nephropathy by 12 weeks.
Acute rejection is the main differential diagnosis of BKVN. BK virus nephropathy could be differentiated with BKV inclusions and immunohistologic analyses. In addition, it is important to correlate histologic findings with PCR evidence of viremia.
There are no available antiviral medications for BKV infections, and there are few controlled studies available on management of BKV infection in renal transplant recipients. The concomitant administration of these agents with immunosuppression reduction has been reported in only uncontrolled retrospective observational studies; therefore, it is difficult to make firm conclusions about their therapeutic efficacy. The common approach for BKV infection management is active screening every 3 months after renal transplant; with any levels of BKV viremia, immunosuppression should be reduced and there should be continuous follow-up of BKV viremia levels using quantitative PCR and renal function tests. Newer options, including cellular immunotherapy, may carry potential hope for treatment of BKV infection.
References:
Volume : 18
Issue : 6
Pages : 659 - 670
DOI : 10.6002/ect.2019.0254
From the 1Nephrology Department, Faculty of Medicine, Suez Canal University,
Egypt; the 2Microbiology Department, Faculty of Medicine, Suez Canal University,
Egypt; the 3Pathology Department and 4Nephrology and Transplantation Department,
Sheffield Teaching Hospitals, United Kingdom; and the 5Institute of Medical
Sciences, University of Liverpool, Liverpool, United Kingdom
Acknowledgements: The authors have no sources of funding for this study and have
no conflicts of interest to declare.
Corresponding author: Ahmed Halawa, Consultant Transplant Surgeon, Sheffield
Teaching Hospitals, Associate Professor, University of Liverpool, Liverpool, UK
E-mail: ahmed.halawa@liverpool.ac.uk
Figure 1. Three Urine Decoy Cells With the Characteristic Large Viral Inclusion Replacing the Normal Chromatin
Figure 2. Marked Acute Tubular Necrosis With Significant Tubulitis Raises Concerns for Concurrent Rejection
Figure 3. Early Stage With Minimal Inflammation, No Inclusions, and Normal Tubular Epithelial Cells
Figure 4. Focal Lesions Illustrate the Importance of Adequate Samples Including 2 Cores
Figure 5. Significant Inflammatory Response (Hematoxylin and Eosin) With Evident Inflammatory Cells
Figure 6. Immunohistochemistry Showing Positive SV40 Staining of BK Virus in Renal Tissue
Figure 6. Immunohistochemistry Showing Positive SV40 Staining of BK Virus in Renal Tissue
Figure 8. Intranuclear Spherical Viral Particles Seen in Tubular Epithelial Cells on Electron Microscopy (×10 000).49
Figure 8. Intranuclear Spherical Viral Particles Seen in Tubular Epithelial Cells on Electron Microscopy (×10 000).49
Figure 10. Outlined Recommendations for BK Virus Screening, Diagnosis, and Management
Figure 10. Outlined Recommendations for BK Virus Screening, Diagnosis, and Management
Figure 10. Outlined Recommendations for BK Virus Screening, Diagnosis, and Management
Table 3. Banff Grading of BK Virus Nephritis